phototherapeutics การใช้

• QLT Phototherapeutics Inc . fell C $ 1.50 to C $ 33.
• QLT Phototherapeutics declined C $ 1.70 to C $ 31.30.
• QLT Phototherapeutics Inc . shares fell 1 5 / 8 to 12 5 / 8.
• QLT Phototherapeutics fell 1 / 4 to 11 5 / 8 before trading was halted.
• QLT Phototherapeutics Inc ., Vancouver, British Columbia, 2.3 million shares.
• Imasco Ltd ., Cott Corp ., and QLT PhotoTherapeutics Inc . led consumer products shares higher.
• In other stock activity, QLT Phototherapeutics Inc . shares rose 5 / 8 to 10 7 / 8.
• In other stock activity, QLT Phototherapeutics Inc . shares rose 1 5 / 8 to 11 7 / 8.
• On Thursday, Canadian company QLT Phototherapeutics will try to win panel backing for its lung cancer treatment, Photofrin.
• QLT Phototherapeutics Inc . ( QLT CT ) rose C $ 1.65 to C $ 27.50.
• The U . S . government has approved one photosensitizer, Photofrin, made by Canada's QLT Phototherapeutics.
• QLT Phototherapeutics Inc . shares rose 12 percent after the company said it reacquired certain distribution rights for its Photofrin cancer treatment.
• QLT Phototherapeutics Inc . shares rose 17 percent after the company said it reacquired certain distribution rights for its Photofrin cancer treatment.
• QLT Phototherapeutics Inc . ( QLT CT ) rose as much as C $ 0.20 to C $ 27.20.
• But manufacturer QLT Phototherapeutics is about to ask government permission to sell Visudyne based on the early data, approval that Bressler expects by 2000.
• QLT Phototherapeutics Inc . ( QLT CT ) fell C $ 4.10 to C $ 23.50, a three-month low.
• -- Qlt Phototherapeutics Inc . ( QLTIF US ) was rated " buy " in new coverage by analyst Dawn Blessing at UBS Securities.
• QLT Phototherapeutics Inc . won U . S . Food and Drug Administration approval to sell its light therapy drug Photofrin as a treatment for lung cancer.
• Indeed, announcement of the results touched off a huge gain in the stock of the drug's developer, QLT Phototherapeutics of Vancouver, Canada.
• But manufacturer QLT Phototherapeutics is about to ask U . S . government permission to sell Visudyne based on the early data, approval that Bressler expects by 2000.